Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Early developmental asymmetries in cell lineage trees in living individuals
Fasching, Liana , Jang, Yeongjun , Schreiner, Jeremy D. , Tomasini, Livia , Brady, Melanie , Bae, Taejeong , Sarangi, Vivekananda , Vasmatzis, Nikolaos , Wang, Yifan , Szekely, Anna , Fernandez, Thomas , Leckman, James F. , Abyzov, Alexej , Vaccarino, Flora M. , Schreiner, Jeremy , Tomasini, Livia , Brady, Melanie V , Bae, Taejeong , Vasmatzis, Nikolaos , Wang, Yifan , Szekely, Anna , Fernandez, Thomas V , Abyzov, Alexej , Vaccarino, Flora M , Leckman, James F , Jang, Yeongjun , Tomasi, Simone

Mayo Clinic

Science | March 18, 2021 | Volume: 371 | Issue: 6535 | Pages: 1245-1248

10.1126/science.abe0981 | PMID 33737484 Get It

Genomic sleuthing spots early divergence After fertilization, the human zygote divides into two cells. Fasching et al. used genomic analysis from cellular samples taken much later in development to back-calculate the cell division trees that went before. Although the first cell division in human development looks symmetrical from the outside, the fates followed by daughter cells from each of those first two blastomeres are anything but the same. As much as 90% of blood cells are derived from just one of the first two blastomeres. Science , this issue p. 1245
Statistical estimation and comparison of group-specific bivariate correlation coefficients in family-type clustered studies
Luo, Jingqin , Gao, Feng , Liu, Jingxia , Wang, Guoqiao , Chen, Ling , Fagan, Anne M. , Day, Gregory S. , Vöglein, Jonathan , Chhatwal, Jasmeer P. , Committee, the Dominantly Inherited Alzheimer Network (DIAN) Steering, Day, Gregory S , Vöglein, Jonathan , Gao, Feng , Luo, Jingqin , Liu, Jingxia , Xiong, Chengjie , Committee, the Dominantly Inherited Alzheimer Network (DIAN) Steering

Mayo Clinic

Journal of Applied Statistics | March 18, 2021 | Volume: 49 | Issue: 9 | Pages: 2246-2270

10.1080/02664763.2021.1899141 | PMID 35755087 Get It

Esophageal Epidermoid Metaplasia: Clinical Characteristics and Risk of Esophageal Squamous Neoplasia
Kamboj, Amrit K. , Gibbens, Ying , Hagen, Catherine E. , Wang, Kenneth K, Iyer, Prasad G. , Katzka, David A. , Gibbens, Ying Y, Hagen, Catherine E

Mayo Clinic

American Journal of Gastroenterology | March 18, 2021 | Volume: 116 | Issue: 7 | Pages: 1533-1536

10.14309/ajg.0000000000001225 | PMID 33734117 Get It

INTRODUCTION: Esophageal epidermoid metaplasia (EEM) is a rare disease. METHODS: Patients with EEM diagnosed between 2014 and 2020 were reviewed. RESULTS: Forty EEM cases were identified. EEM occurred in 9 (23%) patients before, concordant, or after esophageal squamous cell carcinoma (ESCC). EEM was associated with previous esophageal lichen planus in 5 patients, Barrett's esophagus 7, and esophageal adenocarcinoma 1. EEM was focal in 28 (70%) or diffuse in 12 (30%) and not detected in 45% on recent previous endoscopy. DISCUSSION: EEM is a premalignant underrecognized condition associated with multiple conditions. Close follow-up or endoscopic treatment may be warranted because of its ESCC association.
Sustained Release GLP‑1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson’s Disease
Wang, Vicki, Kuo, Tung‐Tai , Huang, Eagle Yi-Kung, Ma, Kuo-Hsing, Fu, Zhao-Yang, Lai, Li-Wen, Jung, Jin Ho , Choi, Hoi-II, Choi, Doo‐Sup , Li, Yazhou , Olson, Lars, Hoffer, Barry J. , Choi, Doo-Sup , Huang, Eagle Yi‐Kung, Ma, Kuo‐Hsing , Chou, Yu‐Ching , Olson, Lars, Greig, Nigel H. , Chen, Yuan-Hao

Mayo Clinic

ACS Pharmacology & Translational Science | March 17, 2021 | Volume: 4 | Issue: 2 | Pages: 858-869

10.1021/acsptsci.1c00013 | PMID 33860208 Get It

Abstract GLP-1 agonists have become increasingly interesting as a new Parkinson’s disease (PD) clinical treatment strategy. Additional preclinical studies are important to validate this approach and define the disease stage when they are most effective. We hence characterized the efficacy of PT320, a sustained release formulation of the long acting GLP-1 agonist, exenatide, in a progressive PD (MitoPark) mouse model. A clinically translatable biweekly PT320 dose was administered starting at 5 weeks of age and longitudinally evaluated to 24 weeks, and multiple behavioral/cellular parameters were measured. PT320 significantly improved spontaneous locomotor activity and rearing in MitoPark PD mice. “Motivated” behavior also improved, evaluated by accelerating rotarod performance. Behavioral improvement was correlated with enhanced cellular and molecular indices of dopamine (DA) midbrain function. Fast scan cyclic voltammetry demonstrated protection of striatal and nucleus accumbens DA release and reuptake in PT320 treated MitoPark mice. Positron emission tomography showed protection of striatal DA fibers and tyrosine hydroxylase protein expression was augmented by PT320 administration. Early PT320 treatment may hence provide an important neuroprotective therapeutic strategy in PD.
Novel Genetic Variant Predicts Surgical Recurrence Risk in Crohn’s Disease Patients
Wang, Ming‐Hsi , Friton, Jessica, Raffals, Laura E. , Leighton, Jonathan A. , Pasha, Shabana F., Picco, Michael F., Monroe, Kelly, Nix, Billy D., Newberry, Rodney D. , Faubion, William A. , Friton, Jessica J, Newberry, Rodney D

Mayo Clinic

Inflammatory Bowel Diseases | March 16, 2021 | Volume: 27 | Issue: 12 | Pages: 1968-1974

10.1093/ibd/izaa362 | PMID 33724339 Get It

Abstract Background We aimed to identify a model of clinical and genetic risk factors through hypothesis-free search across genome that can predict the surgical recurrence risk after the first abdominal surgery in CD patients. Materials and Methods Two independent inflammatory bowel disease (IBD) cohort studies were used to derive and validate the genetic risk profile. The study subjects were genotyped using Illumina Immunochip custom genotyping array. Surgical recurrence was defined as having the second or more abdominal bowel resections after the first abdominal surgery at the time of study enrollment; nonsurgical recurrence was defined as having no further abdominal resection after the first abdominal surgery. Results Among 372 CD patients who had at least 1 abdominal surgery at the study enrollment, 132 (35.5%) had subsequent surgical recurrence after their first abdominal surgery, and 240 (64.5%) required no subsequent abdominal surgery at the end of follow up. Among clinical factors, multivariable analysis showed that history of immunomodulatory use (odds ratio [OR], 3.96; P = 0.002) and early era of CD first surgery (OR, 1.12; P = 1.01E-04) remained significant. Genotypic association tests identified a genome-wide significant locus rs2060886 in TCF4 at chr18q21.2 associated with surgical recurrence risk (OR, dom, 4.10 [2.37–7.11]; P = 4.58E-08). Conclusions Novel genetic locus rs2060886 in TCF4 was associated with surgical recurrence risk at genome-wide significance level among CD patients after their first abdominal surgery. Early era of CD first intestinal surgery predicts higher surgical recurrence risk. These results suggest that genetic variants may help guide the CD management strategy in patients at the highest risk of repeated abdominal surgeries.
Improved Prediction of Imminent Progression to Clinically Significant Memory Decline Using Surface Multivariate Morphometry Statistics and Sparse Coding
Stonnington, Cynthia M. , Initiative, for the Alzheimer’s Disease Neuroimaging, Wu, Jianfeng , Bauer, Robert, Devadas, Vivek, Reiman, Eric M. , Caselli, Richard J. , Locke, Dona E.C. , Initiative, for the Alzheimer’s Disease Neuroimaging, Zhang, Jie , Shi, Jie , Su, Yi , Chen, Kewei , Wang, Yalin

Mayo Clinic

Journal of Alzheimer's Disease | March 16, 2021 | Volume: 81 | Issue: 1 | Pages: 209-220

10.3233/jad-200821 | PMID 33749642 Get It

Background: Besides their other roles, brain imaging and other biomarkers of Alzheimer’s disease (AD) have the potential to inform a cognitively unimpaired (CU) person’s likelihood of progression to mild cognitive impairment (MCI) and benefit subject selection when evaluating promising prevention therapies. We previously described that among baseline FDG-PET and MRI measures known to be preferentially affected in the preclinical and clinical stages of AD, hippocampal volume was the best predictor of incident MCI within 2 years (79%sensitivity/78%specificity), using standard automated MRI volumetric algorithmic programs, binary logistic regression, and leave-one-out procedures. Objective: To improve the same prediction by using different hippocampal features and machine learning methods, cross-validated via two independent and prospective cohorts (Arizona and ADNI). Methods: Patch-based sparse coding algorithms were applied to hippocampal surface features of baseline TI-MRIs from 78 CU adults who subsequently progressed to amnestic MCI in approximately 2 years (“progressors”) and 80 matched adults who remained CU for at least 4 years (“nonprogressors”). Nonprogressors and progressors were matched for age, sex, education, and apolipoprotein E4 allele dose. We did not include amyloid or tau biomarkers in defining MCI. Results: We achieved 92%prediction accuracy in the Arizona cohort, 92%prediction accuracy in the ADNI cohort, and 90%prediction accuracy when combining the two demographically distinct cohorts, as compared to 79%(Arizona) and 72%(ADNI) prediction accuracy using hippocampal volume. Conclusion: Surface multivariate morphometry and sparse coding, applied to individual MRIs, may accurately predict imminent progression to MCI even in the absence of other AD biomarkers.
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival
Wenzel, Lari , Osann, Kathryn , McKinney, Chelsea , Cella, David , Fulci, Giulia , Scroggins, Mary Jackson, Lankes, Heather A. , Wang, Victoria , Nephew, Kenneth P. , Maxwell, G. Larry , Mok, Samuel C. , Miller, Austin , Mannel, Robert S., Gray, Heidi J. , Hanjani, Parviz, Huh, Warner K. , Spirtos, Nick M. , Sharma, Sudarshan , Santin, Alessandro D. , Sperduto, Paul W. , Lele, Shashikant B., Burger, Robert A. , Monk, Bradley J. , Birrer, Michael J. , Miller, Austin , Spirtos, Nick , Glaser, Gretchen , Monk, Bradley J , Mok, Samuel C , Conrads, Thomas , Leitão, Mario M. , Glaser, Gretchen

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 15, 2021 | Volume: 113 | Issue: 10 | Pages: 1369-1378

10.1093/jnci/djab034 | PMID 33729494 Get It

Abstract Background There is a critical need to identify patient characteristics associated with long-term ovarian cancer survival. Methods Quality of life (QOL), measured by the Functional Assessment of Cancer Therapy-Ovarian-Trial Outcome Index (FACT-O-TOI), including physical, functional, and ovarian-specific subscales, was compared between long-term survivors (LTS) (8+ years) and short-term survivors (STS) (<5 years) of GOG 218 at baseline; before cycles 4, 7, 13, 21; and 6 months post-treatment using linear and longitudinal mixed models adjusted for covariates. Adverse events (AEs) were compared between survivor groups at each assessment using generalized linear models. All P values are 2-sided. Results QOL differed statistically significantly between STS (N = 1115) and LTS (N = 260) (P < .001). Baseline FACT-O-TOI and FACT-O-TOI change were independently associated with long-term survival (odds ratio = 1.05, 95% confidence interval = 1.03 to 1.06 and odds ratio = 1.06, 95% confidence interval = 1.05 to 1.07, respectively). A 7-point increase in baseline QOL was associated with a 38.0% increase in probability of LTS, and a 9-point increase in QOL change was associated with a 67.0% increase in odds for LTS. QOL decreased statistically significantly with increasing AE quartiles (cycle 4 quartiles: 0-5 vs 6-8 vs 9-11 vs ≥12 AEs, P = .01; cycle 21 quartiles: 0-2 vs 3 vs 4-5 vs ≥6 AEs, P = .001). Further, LTS reported statistically significantly better QOL compared with STS (P = .03 and P = .01, cycles 4 and 21, respectively), with similar findings across higher AE grades. Conclusions Baseline and longitudinal QOL change scores distinguished LTS vs STS and are robust prognosticators for long-term survival. Results have trial design and supportive care implications, providing meaningful prognostic value in this understudied population.
Hemispherectomy Outcome Prediction Scale: Development and validation of a seizure freedom prediction tool
Weil, Alexander G. , Lewis, Evan , Ibrahim, George M. , Tseng, Chi‐Hong , Zhou, Xinkai , Lin, Kao‐Min, Cai, Lixin , Liu, Qingzhu , Lin, Jiuluan , Mathern, Gary W. , Smyth, Matthew D. , O’Neill, Brent R., Dudley, Roy , Ragheb, John , Bhatia, Sanjiv, Delev, Daniel , Ramantani, Georgia , Zentner, Josef , Dorfer, Christian , Feucht, Martha , Czech, Thomas , Bollo, Robert J. , Issabekov, Galymzhan , Zhu, Hongwei , Connelly, Mary Shane, Steinbok, Paul , Zhang, Kai , Hidalgo, Eveline Teresa , Weiner, Howard L. , Lapalme‐Remis, Samuel , Tripathi, Manjari , Chandra, P. Sarat , Hader, Walter , Wang, Feng‐Peng , Champagne, Pierre Olivier, Budke, Marcelo , Pérez-Jiménez, María Ángeles, Raftapoulos, Christian, Finet, Patrice, Michel, Pauline, Schaller, Karl , Malone, Christian Cantillano, Pociecha, Juan , Chamorro, Noelia, Muro, Valeria L., Lehe, Marec von , Vieker, Silvia, Oluigbo, Chima , Gaillard, William D. , Khateeb, Mashael Al, Alotaibi, Faisal , Krayenbühl, Niklaus , Bolton, Jeffrey , Ramantani, Georgia , Dorfer, Christian , Feucht, Martha , Wong-Kisiel, Lily, Tripathi, Manjari , Sarat Chandra, Poodipedi , Gaillard, William D , Fallah, Aria , von Lehe, Marec , Weil, Alexander G , Oluigbo, Chima O , Kola, Olivia , Zhou, Wen-Jing , Ojemann, Jeffrey G. , Wang, Anthony , Connelly, Mary, Zhang, Jianguo , Wong‐Kisiel, Lily C. , Wang, Feng‐Peng, Yao, Yi , Guo, Qiang , Li, Shao‐Chun, Stienen, Martin Nikolaus , Baro, Valentina , Pearl, Phillip L. , Fallah, Aria

Mayo Clinic

Epilepsia | March 13, 2021 | Volume: 62 | Issue: 5 | Pages: 1064-1073

10.1111/epi.16861 | PMID 33713438 Get It

AbstractObjectiveTo develop and validate a model to predict seizure freedom in children undergoing cerebral hemispheric surgery for the treatment of drug‐resistant epilepsy.MethodsWe analyzed 1267 hemispheric surgeries performed in pediatric participants across 32 centers and 12 countries to identify predictors of seizure freedom at 3 months after surgery. A multivariate logistic regression model was developed based on 70% of the dataset (training set) and validated on 30% of the dataset (validation set). Missing data were handled using multiple imputation techniques.ResultsOverall, 817 of 1237 (66%) hemispheric surgeries led to seizure freedom (median follow‐up = 24 months), and 1050 of 1237 (85%) were seizure‐free at 12 months after surgery. A simple regression model containing age at seizure onset, presence of generalized seizure semiology, presence of contralateral 18‐fluoro‐2‐deoxyglucose–positron emission tomography hypometabolism, etiologic substrate, and previous nonhemispheric resective surgery is predictive of seizure freedom (area under the curve = .72). A Hemispheric Surgery Outcome Prediction Scale (HOPS) score was devised that can be used to predict seizure freedom.SignificanceChildren most likely to benefit from hemispheric surgery can be selected and counseled through the implementation of a scale derived from a multiple regression model. Importantly, children who are unlikely to experience seizure control can be spared from the complications and deficits associated with this surgery. The HOPS score is likely to help physicians in clinical decision‐making.
Macroscopic hematuria in wasp sting patients: a retrospective study
Wang, Maohe, Prince, Singh, Tang, Yong, Zhong, Xiang, Chen, Shasha, Li, Guisen , Wang, Li, Wang, Wei, Singh, Prince , Wang, Maohe, Prince, Singh, Tang, Yong, Zhong, Xiang, Chen, Shasha, Li, Guisen , Wang, Li, Wang, Wei

Mayo Clinic

Renal Failure | March 12, 2021 | Volume: 43 | Issue: 1 | Pages: 500-509

10.1080/0886022x.2021.1896547 | PMID 33706645 Get It

Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma
Sun, Guangxi , Liang, Jiayu, Yin, Xiaoxue , Zhang, Mengni , Yao, Jin , He, Ning , Armstrong, Cameron M. , Zheng, Linmao , Sun, Xiaomeng , Yang, Xiaoxia , Zhao, Wanbin , Liao, Banghua , Pan, Xiuyi , Yang, Ling , Zhao, Jinge , Dai, Jindong, Shen, Yali , Huang, Rui , Liu, Jiandong , Wang, Zhipeng , Ni, Yuchao , Wei, Qiang , Zhou, Qiao , Liu, Zhenhua , Shen, Pengfei , Chen, Ni , Zeng, Hao , Sun, Guangxi , Chen, Junru , Zhang, Xingming , Zhu, Sha , Nie, Ling , Chen, Yahong , Zhang, Haoran , Liu, Jiyan , Li, Xiang , Huang, Haojie

Mayo Clinic

No container title available | March 11, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-296261/v1 Get It

Abstract TFE3-translocation renal cell carcinoma (TFE3-tRCC) is a rare and heterogeneous subtype of kidney cancer that has no standard treatment for advanced disease. We described comprehensive molecular characteristics of 63 untreated primary TFE3-tRCCs based on whole-exome and RNA sequencing. TFE3-tRCC is highly heterogeneous, both clinicopathologically and genotypically. ASPSCR1-TFE3 fusion, certain fusion isoforms and high somatic copy number alteration burdens were associated with aggressive features and poor outcomes. Apart from tumors with MED15-TFE3 fusion, most TFE3-tRCCs exhibited low PD-L1 expression and low T-cell infiltration. Unsupervised transcriptomic analysis revealed five molecular clusters with distinct angiogenesis, stroma, proliferation and KRAS down signatures, which showed association with fusion patterns and prognosis. Specifically, the high angiogenesis/stroma/proliferation cluster exclusively consisted of tumors with ASPSCR1-TFE3 fusion, which was likely to benefit from combination of immune checkpoint and anti-angiogenesis inhibitors. Our findings reveal the genomic and transcriptomic features of TFE3-tRCC and provide insights into precision medicine for this disease.